Skip to content
Evevident
Original paper
2005NEJMHematology/Oncology

HERA

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

RCTBreast cancer

On this page

Overview

Adjuvant trastuzumab improved disease-free survival in HER2-positive early breast cancer.

Clinical takeaway

HERA helped establish HER2-targeted therapy as a standard adjuvant treatment, transforming HER2-positive breast cancer from a poor-prognosis subtype into a targetable disease.

Key result

One year of trastuzumab reduced recurrence events versus observation after chemotherapy.

Practice impact

HER2 testing and adjuvant trastuzumab became routine in eligible early breast cancer.

Evidence

Study design

Randomized open-label trial after completion of surgery and chemotherapy.

Enrollment

5,081

Follow-up

Median 1 year at interim efficacy report; later long-term follow-up confirmed durable benefit.

Geography

Multinational

Clinical question

Does adjuvant trastuzumab improve disease-free survival after chemotherapy in HER2-positive early breast cancer?

Population

  • Women with HER2-positive early breast cancer who had completed locoregional therapy and chemotherapy.

Intervention

Trastuzumab every 3 weeks for 1 year after chemotherapy.

Comparator

Observation after chemotherapy.

Primary outcome

Disease-free survival.

Adjuvant trastuzumab substantially reduced recurrence risk after chemotherapy in HER2-positive early breast cancer.

Hazard ratio / 0.54 / CI 95% CI 0.43-0.67 / p=<0.0001

Key results

  • One year of trastuzumab significantly improved disease-free survival.
  • Distant recurrence was reduced.
  • Cardiac dysfunction was more common with trastuzumab and required monitoring.

Harms

  • Symptomatic congestive heart failure and reduced left ventricular ejection fraction were more common with trastuzumab.
  • Infusion reactions and cardiotoxicity monitoring are practical concerns.

Clinical Use

When to cite

  • When explaining why HER2-positive early breast cancer receives adjuvant trastuzumab-based therapy.

Practice impact

  • Made HER2 testing and HER2-targeted adjuvant therapy central to early breast cancer management.

Applicability

  • Patients with HER2-positive early breast cancer eligible for adjuvant systemic therapy and cardiac monitoring.

Limitations

  • Open-label design.
  • Contemporary regimens may use different chemotherapy backbones and additional HER2-targeted agents.

Common misinterpretations

  • Do not ignore cardiac risk; trastuzumab benefit comes with a need for baseline and interval cardiac assessment.

Citation

Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684. doi:10.1056/NEJMoa052122

One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.